Agonists vs. Antagonists for the Treatment of Advanced Prostate Cancer

by Thomas E. Keane, MD | Feb 2019

 

How to cite: Keane, Thomas “Agonists vs. Antagonists for the Treatment of Advanced Prostate Cancer”. January, 2019. Accessed Dec 2024. https://grandroundsinurgology.com/agonists-vs-antagonists-for-the-treatment-of-advanced-prostate-cancer/

Agonists vs. Antagonists for the Treatment of Advanced Prostate Cancer – Summary:

Thomas Keane, MD, Chair of Urology at the Medical University of South Carolina, discusses the choice between agonists and antagonists when making treatment decisions on the use of androgen deprivation therapy (ADT) for advanced prostate cancer. Additionally, he addresses concerns over the 28-day formulation of antagonists.

 

ABOUT THE AUTHOR

+ posts

Thomas E. Keane, MD, is Professor and Chairman of the Department of Urology at the Medical University of South Carolina in Charleston. Dr. Keane specializes in managing prostate, bladder, and renal cancers.

An avid researcher, Dr. Keane has served as principal investigator or co-investigator on more than 20 major clinical and preclinical studies. Much of his work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate the efficacy of new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a United States patent for sphingolipid derivatives and their use.

Dr. Keane’s research has led to publication of more than 100 articles peer-reviewed in such journals as The Journal of Urology, Urologic Oncology, and the Journal of Vascular Surgery. He provides editorial services to publications ranging from Urology to the International Journal of Cancer and is co-editor of the text Glenn’s Urologic Surgery, 6th, 7th, and 8th Editions. He is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.